Core Viewpoint - Beixin Life Technology Co., Ltd. has successfully listed on the STAR Market, marking a significant milestone as the first medical device company in the cardiovascular field to do so since 2024, breaking the long-standing monopoly of foreign giants in the high-end interventional medical device sector [1] Group 1: Market Opportunity and Product Innovation - Cardiovascular diseases are a leading health threat globally, with 330 million patients in China, including approximately 11.39 million with coronary heart disease, indicating a rising prevalence [2] - The company focuses on addressing critical clinical pain points in cardiovascular diagnosis and treatment, having developed innovative solutions such as the Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR) systems, which enhance the precision of coronary interventions [2][3] - The IVUS system is the first domestically approved high-definition product, while the FFR system is recognized as a "gold standard" for coronary heart disease diagnosis, significantly reducing patient burden and improving treatment accuracy [3] Group 2: Research and Development Strength - The company has invested 438 million yuan in R&D from 2022 to June 2025, with a projected R&D expense ratio of 35.65% in 2024, surpassing industry averages [4] - Beixin Life has secured 185 domestic and international patents, including 86 invention patents, covering key technologies in ultrasound transducers and image algorithms [4] Group 3: Product Portfolio and Market Penetration - The company has developed a comprehensive product ecosystem covering diagnostic devices, therapeutic instruments, and supporting consumables, enhancing procurement stickiness for hospitals [5] - As of September 2025, Beixin Life's products are available in 30 provinces and approximately 1,000 hospitals in China, with over 70% being tertiary hospitals [7] Group 4: Financial Performance and Growth - The company's revenue surged from 92.45 million yuan in 2022 to 317 million yuan in 2024, representing a growth of over 340%, with a year-on-year increase of 71.29% in 2024 [7] - Despite price pressures from centralized procurement, the company maintained a gross margin of 63.32% in 2024, demonstrating resilience and effective cost control [10] Group 5: Industry Trends and Future Outlook - The cardiovascular interventional device market is projected to grow significantly, driven by an aging population and supportive policies, with the precision PCI market expected to expand from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, at a CAGR of approximately 21.1% [11] - The penetration rates for FFR and IVUS in China are currently low, at 3.4% and under 5% respectively, indicating substantial growth potential as clinical awareness increases and domestic product prices decrease [13] - Beixin Life aims to leverage its first-mover advantage in the domestic market and its CE MDR certification to capture a larger share of the global cardiovascular interventional device market [17][19]

Core Insights - The article emphasizes the importance of technological self-reliance and innovation as key drivers for building a modern socialist country, as highlighted by national leaders during their first local inspection in the "14th Five-Year Plan" period [1] - The FOF ecosystem of Kunyuan Asset is accelerating its IPO activities, with two significant companies, Beixin Life (688712.SH) and Aixin Yuanzhi (00600.HK), successfully listing on the stock exchanges within a short span of six days, marking a strong start for the year [1][4] Company Highlights - Beixin Life (688712.SH) is recognized as the first domestic company to focus on intelligent and precise intervention in cardiovascular diseases, successfully listing on the Sci-Tech Innovation Board and achieving multiple industry milestones [4][6] - Aixin Yuanzhi (00600.HK) specializes in AI visual chip design and has become a leading player in the high-end AI chip market, successfully listing on the Hong Kong Stock Exchange [7][10] Market Trends - The article discusses the strategic focus on future industries such as quantum technology, biomanufacturing, and AI, which are identified as new economic growth points in the "14th Five-Year Plan" [4] - The successful IPOs of Beixin Life and Aixin Yuanzhi reflect the growing trend of domestic high-end medical devices and AI chips, indicating a shift from import substitution to original technology-driven innovation [5][10] Investment Strategy - Kunyuan Asset's FOF ecosystem aims to support high-quality tech companies through early-stage investments, alleviating financial pressures and allowing firms to focus on core technological innovations [9] - The article highlights the importance of capital market development in supporting the growth of tech enterprises, aligning with national strategies for economic and social development [8][10]

Group 1: IPO Overview - Zhuozheng Medical Holdings Limited (Zhuozheng Medical) was listed on the Hong Kong Stock Exchange on February 6, 2026, under the stock code "2677" [3] - The IPO raised a total of HKD 284 million by issuing 4,750,000 shares, with a subscription rate of 2730.73 times for the Hong Kong public offering and 5.79 times for the international offering [3] - Zhuozheng Medical's cornerstone investors include notable figures and companies such as He Xiaopeng, CEO of Xiaopeng Motors, and leading firms in the AI sector [4] Group 2: Company Performance - Zhuozheng Medical focuses on the high-end medical service market, targeting affluent consumers who prefer personalized healthcare [4] - The company ranked first and second among private high-end comprehensive medical service institutions in China based on the number of cities covered and patient visits projected for 2024 [4] - Revenue figures for Zhuozheng Medical from 2022 to 2024 are as follows: CNY 473 million, CNY 690 million, and CNY 959 million, with a compound annual growth rate (CAGR) of 42.2% [4] - Gross profit for the same period was CNY 44 million, CNY 134 million, and CNY 226 million, with a CAGR of 126.7% [4] - The company achieved profitability in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [4] Group 3: North Star Life - North Star Life Technology Co., Ltd. (North Star Life) was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2026, under the stock code "688712.SH" [6] - North Star Life specializes in innovative medical devices for cardiovascular disease diagnosis and treatment, having launched 11 products and having 6 in development as of September 30, 2025 [6][8] - The company's core products include the IVUS system and FFR system, both of which are recognized as leading innovations in China [7] Group 4: LuKe Technology - LuKe Technology (Beijing) Co., Ltd. (LuKe Technology) submitted its prospectus for listing on the Hong Kong Stock Exchange on February 6, 2026 [10] - Established in 2014, LuKe Technology focuses on smart locks and home security solutions, leading the market in China with a 5.8% share in 2024 [11] - The company reported revenues of CNY 1.015 billion in 2023 and CNY 1.086 billion in 2024, with a projected increase in revenue for the first three quarters of 2025 [11] Group 5: Tianyi Space Technology - Tianyi Space Technology Co., Ltd. (Tianyi Research Institute) signed a counseling agreement to initiate its A-share IPO process on January 27, 2026 [14] - The company has successfully launched 38 satellites, filling a gap in China's commercial SAR satellite market [15] - Tianyi's services include high-quality SAR data for various applications, contributing to disaster prevention and infrastructure monitoring [15] Group 6: BoRuiKang Technology - BoRuiKang Technology (Shanghai) Co., Ltd. (BoRuiKang) initiated its IPO process on the Sci-Tech Innovation Board on February 4, 2026 [18] - The company specializes in brain-machine interface technology and has successfully conducted surgeries using its product, NEO, in multiple hospitals [19] - BoRuiKang has received significant investments from various venture capital firms and aims to enhance its product capabilities in future iterations [19]

Summary of Key Points Core Viewpoint - The A-share IPO market is active with three companies approved for listing, while the Hong Kong IPO market continues to thrive, particularly in the innovative drug and high-end manufacturing sectors, with several key players making significant moves [2][6]. Group 1: A-share IPO Approvals - Three companies received approval for IPOs this week: Guangdong Huahui Intelligent Equipment Co., Ltd., Anhui Xinfeng New Energy Technology Co., Ltd., and Shandong Chunguang Technology Group Co., Ltd. [2][3][4]. - Huahui Intelligent focuses on high-end intelligent equipment and has seen rapid revenue growth, projecting over 4.2 billion yuan in revenue for 2024 and over 620 million yuan in net profit [3]. - Xinfeng Technology specializes in thermal management components for electric vehicles, with projected revenues of 6 billion yuan in 2024 and 13.81 billion yuan in 2025 [4][5]. - Chunguang Group leads in the production of soft magnetic ferrite powder, with revenues of 10.15 billion yuan in 2022 and a planned fundraising of 7.51 billion yuan for its IPO [5]. Group 2: Hong Kong IPO Market Activity - The Hong Kong IPO market welcomed five new listings, including four companies and one on the Sci-Tech Innovation Board, covering diverse sectors such as chemical new materials and cardiovascular medical devices [6][7]. - Guoen Technology debuted on the Hong Kong Stock Exchange, raising approximately 1 billion HKD, with plans for expansion in Thailand and domestic production [6]. - Beixin Life, the first medical device company listed on the Sci-Tech Innovation Board, saw its stock price surge by 183.33% on its first day, focusing on cardiovascular intervention devices [7]. - Leading companies in the PCB equipment sector, such as Dazhu CNC, raised significant funds for expansion into Southeast Asia, while Zhuozheng Medical and Muyuan Foods had mixed performances post-listing [8]. Group 3: Upcoming IPOs and Market Trends - The Hong Kong IPO market continues to be driven by hard technology, with companies like Danuo Pharmaceutical and Xian Dao Intelligent preparing for their listings, focusing on innovative drugs and lithium battery equipment [9][10]. - Danuo Pharmaceutical is set to raise funds for global clinical advancements, with its core product showing promising clinical data [9]. - Xian Dao Intelligent aims to raise 41.66 billion HKD, with a significant projected profit increase of 424% by 2025, expanding its services beyond lithium battery equipment [10]. - Wolong Nuclear Materials is also preparing for an IPO, focusing on new materials and global capacity expansion, with a fundraising target of up to 27.34 billion HKD [11].

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. (Beixin Life) officially listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2026, marking a significant listing case after the resumption of the fifth set of listing standards [1][15]. Company Overview - Beixin Life was founded on December 11, 2015, by Dr. Song Liang, a biomedical engineering expert, in collaboration with seasoned professionals from the medical industry [2][17]. - The company focuses on the cardiovascular precision intervention field, addressing clinical needs in coronary artery disease, peripheral vascular disease, and atrial fibrillation [5][19]. - Beixin Life has evolved from a single-product company to a comprehensive medical device enterprise with 11 commercialized products and 6 products under research, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [5][19]. Product Innovation - The FFR system, Beixin Life's first breakthrough product, received approval from the National Medical Products Administration in 2020, becoming the first domestically produced gold standard FFR product [6][20]. - The IVUS system, launched in July 2022, is China's first domestically developed 60MHz high-definition IVUS product and the fastest in terms of retraction speed and cross-sectional imaging speed globally [6][20]. - As of June 30, 2025, Beixin Life holds 185 authorized patents domestically and internationally, including 86 invention patents and 14 PCT international patent applications [6][20]. Financial Performance - From 2022 to 2024, Beixin Life's revenue is projected to grow from 92 million yuan to 317 million yuan, with a year-on-year growth of 72% in 2024, primarily driven by the rapid sales growth of the IVUS system [7][21]. - The company's net profit attributable to shareholders is expected to improve from a loss of 290 million yuan in 2022 to a loss of 4.4 million yuan in 2024, with a profit of 20.61 million yuan in the first quarter of 2024 [7][21]. - By the end of 2024, Beixin Life's products had entered approximately 1,000 hospitals globally, covering 30 provinces and cities in China, and expanding to over ten overseas countries, with overseas revenue reaching 38.83 million yuan, a nearly 160% increase year-on-year [7][21]. Investment and Support - Sequoia China has participated in at least five rounds of financing for Beixin Life, holding 10.1759% of the company's shares, making it the second-largest shareholder [8][9][23]. - The support from investors has been crucial for Beixin Life's development, with a focus on the cardiovascular precision diagnosis market [8][9][23]. Market Outlook - The innovative medical device industry is a key strategic emerging industry supported by national policies, with the cardiovascular intervention device market expected to grow at a compound annual growth rate of 10.2%, projected to exceed 90 billion yuan by 2026 [11][26]. - Despite the promising outlook, Beixin Life faces challenges such as price declines due to centralized procurement and competition from both domestic and international companies in the IVUS and FFR markets [12][26]. - The listing of Beixin Life signifies the transition of Chinese innovative medical device companies from technology followers to strong competitors in the global market [12][27].

Core Viewpoint - Beixin Life Technology Co., Ltd. successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone for the company and the medical device industry in 2024 [1][3]. Company Overview - Beixin Life is the first medical device company to successfully list under the fifth set of standards of the Sci-Tech Innovation Board and the first medical device company to list in 2024 [1]. - The company focuses on cardiovascular disease diagnosis and treatment, with core products including the IVUS system and FFR system, which are recognized for their innovation and clinical significance [3][5]. Product Highlights - The IVUS system is China's first domestically developed 60MHz high-definition and high-speed IVUS product, designed to guide percutaneous coronary intervention (PCI) strategies [3]. - The FFR system is considered the gold standard for PCI treatment guidance and has received high-level recommendations from various guidelines and expert consensus [3][5]. Research and Development - Beixin Life emphasizes independent research and technological innovation, establishing multiple core technology platforms to support product upgrades and expansions [4]. - The company has a dedicated R&D team of 109 members, with over 40% holding doctoral or master's degrees, highlighting its commitment to talent as a core competitive advantage [4]. Intellectual Property - Beixin Life has developed a comprehensive intellectual property system, holding 185 authorized patents, including 86 invention patents and 14 PCT international patent applications [5]. Market Position and Future Outlook - The company aims to leverage its listing to enhance innovation, global market expansion, and capital collaboration, positioning itself as a leader in intelligent and precise cardiovascular intervention [6]. - The cardiovascular disease intervention market is seen as a rapidly evolving sector with significant clinical demand, presenting a strategic opportunity for Beixin Life to achieve its vision of becoming a world-class medical technology enterprise [5].

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as the first medical device company to do so in 2024 and the first under the new fifth set of standards for the board [2][12]. Company Overview - Established in 2015, Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to transform clinical practices [6][10]. - The company has launched 11 products and has 6 more in development, covering various categories including IVUS systems and FFR systems [6]. Product Highlights - The core product, the IVUS system, is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [7]. - The FFR system is recognized as the gold standard for PCI treatment guidance and has received high-level recommendations in multiple domestic and international guidelines [7]. - Beixin Life's PFA system is the first in China to be included in breakthrough clinical research at the European Society of Cardiology [8]. Market Impact - The successful launch of Beixin Life's products has filled a significant gap in the domestic market, previously reliant on imported products for precise cardiovascular diagnosis [7][10]. - The company has established a presence in over 30 provinces in China and has clinical applications in more than 1,000 hospitals globally, including in Belgium, Germany, and Italy [8]. Innovation and R&D - Beixin Life emphasizes long-term independent research and technological innovation, having developed four core technology platforms for medical devices [10]. - The company holds 185 domestic and international patents, including 86 invention patents and 14 PCT international patent applications [10]. Future Prospects - The listing is seen as a new starting point for Beixin Life, enabling it to accelerate development in innovation, global market expansion, and capital collaboration [12]. - The cardiovascular intervention field is expected to see significant growth, driven by increasing clinical needs and technological advancements [11]. Investment and Support - Major institutional investors include Sequoia China and Qiming Venture Partners, who have expressed confidence in Beixin Life's innovative capabilities and market potential [14][15]. - The company has received continuous support from its investors, focusing on building a strong product portfolio and enhancing its competitive edge in the market [15][17].

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has received approval for its initial public offering and is set to list on the Sci-Tech Innovation Board, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] Group 1: Company Overview - Beixin Life is a national high-tech enterprise specializing in the research, production, and sales of innovative medical devices for cardiovascular disease diagnosis and treatment [1] - The company is the first in China to have a product combination of intravascular functional FFR and imaging IVUS, establishing a high-performance and high-barrier system for active interventional medical devices [2] Group 2: Product Development and Innovation - As of September 30, 2025, Beixin Life has launched 11 products and has 6 products under research, covering five major categories including IVUS systems and FFR systems [2] - The core product, the IVUS system, is the first domestically developed 60MHz high-definition and high-speed IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [2] Group 3: Financial Performance - In the first half of 2025, sales revenue from FFR pressure microcatheters and IVUS catheters accounted for 82.16% of total sales, indicating the continued dominance of core products in the market [3] - Beixin Life achieved a revenue of 259 million yuan and a net profit of 45.51 million yuan in the first half of 2025, marking its first profitable period [3] Group 4: Intellectual Property and Recognition - As of June 30, 2025, Beixin Life holds 185 authorized patents domestically and internationally, including 86 invention patents and 14 PCT international patent applications [4] - The company has been recognized as a "National Specialized and New 'Little Giant' Enterprise" and has received various awards for its core products, highlighting its technological capabilities and market recognition [4] Group 5: Future Outlook - The upcoming IPO is expected to optimize the company's capital structure, reduce debt risk, and enhance its research and development capabilities [6] - Beixin Life aims to continue advancing its product development and expand the application range of existing products, solidifying its comprehensive platform for cardiovascular disease diagnosis and treatment [6]

Core Viewpoint - The company, Beixin Life, is launching an IPO with 57 million shares at a price of 17.52 yuan per share, aiming to raise funds for the development of interventional medical devices and enhance its production capacity and R&D capabilities [1] Group 1: Company Overview - Beixin Life is recognized as a national-level "specialized and innovative" small giant enterprise and has been awarded the title of a provincial manufacturing champion in Guangdong for 2024 [1] - The company focuses on the research, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1][2] - Beixin Life is the first domestic company to offer a combination of intravascular functional (FFR) and imaging (IVUS) products, addressing a significant gap in the domestic market and reducing reliance on imported products for coronary artery disease diagnosis [1][2] Group 2: Product Development and Market Position - The core product, the IVUS system, is the first domestically developed 60MHz high-definition IVUS product approved in China and the first to be approved for sale in Europe, achieving the highest market share among domestic brands [2] - The FFR system, launched in 2020, captured 30.6% of the domestic market share by 2021, contributing to rapid revenue growth for the company [3] - As of September 30, 2025, the company plans to have launched 11 products and has 6 products in development, covering five major categories including IVUS, FFR, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [2] Group 3: Financial Performance - The company's revenue has shown significant growth, with figures of 92.45 million yuan, 183.98 million yuan, and 316.60 million yuan for the years 2022, 2023, and 2024 respectively [3] - For 2025, the company projects revenue between 520 million yuan and 560 million yuan, representing a year-on-year growth of 64.24% to 76.88%, with net profit expected to be between 78 million yuan and 88 million yuan, indicating a growth of 278.91% to 301.85% [3]

Core Viewpoint - The article discusses the upcoming IPO of Beixin Life (科创板, 6887), highlighting its market position and financial performance in the cardiovascular intervention solutions sector. Group 1: Company Overview - Beixin Life is recognized as a leader in China's cardiovascular precision intervention solutions, focusing on clinical precision diagnosis for coronary artery diseases [2] - The company has a total market capitalization of 6.307 billion yuan and an issuance price of 17.52 yuan per share [2] - The controlling shareholder, Dr. Song Liang, has over 18 years of relevant R&D experience and the core products have received multiple certifications and awards [2] Group 2: Product and Market Position - The core product, the FFR measurement system, held a 30.6% market share in the domestic coronary indication market, ranking second with a 10.4% overall market share [2] - The product pipeline includes seven ongoing projects, with the pulse electric field ablation system currently in clinical trials [2] Group 3: Financial Performance - The company reported revenues of 318 million yuan for 2024, reflecting a 72.09% increase [3] - In the past three years, the company's revenue has shown significant growth: 184 million yuan in 2023 (+99%), and 92 million yuan in 2022 (+78.61%) [3]